Merck’s snapshot of positive data for frontline lung cancer niche triggers a new scramble for quick Keytruda OK
Merck has caught the big wave on frontline lung cancer, and it plans to ride an early positive signal straight through to a quick OK for another lucrative market niche for Keytruda.
This morning the pharma giant posted word that their Keynote-407 trial scored a positive hit on the overall response rate for untreated metastatic squamous non-small cell lung cancer in an interim analysis and they’ve already filed for the approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.